---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-24-000102"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2024-06-05T23:59:59+00:00"
generated_at: "2026-06-01T06:21:02.911656+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Xeris stockholders approve all proposals; ESPP shares increased by 6.64M

## Summary
- Third director nominees elected: Edick, Fairley, Persky (58.5M, 58.5M, 47.4M for).
- Ernst & Young ratified as auditor for FY2024 (99.5M for).
- Advisory vote on executive compensation approved (57.8M for); frequency set at 1 year.
- ESPP amendment approved: evergreen provision removed; shares increased by 6,636,632 to 8,854,709.
- Broker non-votes on director election and advisory items: ~36.2M shares.

## SEC filing metadata
- accession: 0001867096-24-000102
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2024-06-05T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/0001867096-24-000102-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709624000102/xers-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-24-000102
- JSON: https://secwatch.observer/filing/0001867096-24-000102.json
- Plain text: https://secwatch.observer/filing/0001867096-24-000102.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.